Abstract：
The frontline immuno-chemotherapy regimen for HIV-associated non-Hodgkin Lymphoma is dose-adjusted EPOCH ± R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab). Chemotherapy-induced peripheral neuropathy (CIPN), caused by vincristine, is a common adverse effect of EPOCH ± R, negatively impacting long-term patient outcomes. The primary objective of this study was to determine the incidence of CIPN, stratified by HIV status, in patients treated with EPOCH ± R. A retrospective cohort study at a tertiary referral comprehensive cancer center evaluated patients treated with EPOCH ± R from 2011 to 2018. The final sample included 27 patients with HIV compared to 279 without HIV (total n = 306). Overall, the incidence of CIPN was 29.4% (n = 90), including 5 with HIV (18.5%) and 85 without HIV (30.5%). Propensity scores were used to match patients by HIV status. Although no relationship was found between HIV status and neuropathy, CIPN affects too many undergoing treatments for lymphoma, supporting future investigations to minimize toxicities.
摘要：
HIV相关非霍奇金淋巴瘤的一线免疫化疗方案是剂量调整的EPOCH±R（依托泊苷，泼尼松,长春新碱,环磷酰胺,阿霉素,和利妥昔单抗）。化疗诱导的周围神经病变（CIPN），由长春新碱引起,是EPOCH±R的常见不良反应，对患者的长期预后产生负面影响。这项研究的主要目的是确定CIPN的发生率，按艾滋病毒状况分层，在接受EPOCH±R治疗的患者中,三级转诊综合癌症中心的一项回顾性队列研究评估了2011年至2018年接受EPOCH±R治疗的患者.最终样本包括27名HIV患者，而没有HIV的患者为279名（总计n=306）。总的来说,CIPN的发生率为29.4%(n=90)，包括5名HIV感染者（18.5%）和85名HIV感染者（30.5%）。倾向评分用于根据HIV状况匹配患者。尽管没有发现HIV状态和神经病之间的关系，CIPN影响了太多正在接受淋巴瘤治疗的患者，支持未来的调查，以尽量减少毒性。
